On-treatment platelet reactivity through the thromboxane A 2 or P2Y12 platelet receptor pathways is not affected by pelacarsen.

Autor: Karwatowska-Prokopczuk E; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA., Li L; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA., Yang J; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA., Witztum JL; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA., Tsimikas S; Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA. stsimikas@health.ucsd.edu.; Vascular Medicine Program, Sulpizio Cardiovascular Center, University of California San Diego, 9500 Gilman Drive, BSB 1080, La Jolla, CA, 92093-0682, USA. stsimikas@health.ucsd.edu.
Jazyk: angličtina
Zdroj: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2023 Aug; Vol. 56 (2), pp. 226-232. Date of Electronic Publication: 2023 Jun 20.
DOI: 10.1007/s11239-023-02818-6
Abstrakt: Background: Pelacarsen decreases plasma levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPL). It was previously reported that pelacarsen does not affect the platelet count. We now report the effect of pelacarsen on on-treatment platelet reactivity.
Methods: Subjects with established cardiovascular disease and screening Lp(a) levels ≥60 mg per deciliter (~ ≥150 nmol/L) were randomized to receive pelacarsen (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or placebo for 6-12 months. Aspirin Reaction Units (ARU) and P2Y12 Reaction Units (PRU) were measured at baseline and the primary analysis timepoint (PAT) at 6 months.
Results: Of the 286 subjects randomized, 275 had either an ARU or PRU test, 159 (57.8%) were on aspirin alone and 94 (34.2%) subjects were on dual anti-platelet therapy. As expected, the baseline ARU and PRU were suppressed in subjects on aspirin or on dual anti-platelet therapy, respectively. There were no significant differences in baseline ARU in the aspirin groups or in PRU in the dual anti-platelet groups. At the PAT there were no statistically significant differences in ARU in subjects on aspirin or PRU in subjects on dual anti-platelet therapy among any of the pelacarsen groups compared to the pooled placebo group (p > 0.05 for all comparisons).
Conclusion: Pelacarsen does not modify on-treatment platelet reactivity through the thromboxane A 2 or P2Y12 platelet receptor pathways.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: